Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
View Patent ↗The present invention is directed to compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the beta-secretase enzyme is involved.
1. A compound of the formula I:
wherein:
R 1 is selected from the group consisting of:
(1) —C 1-6 alkyl,
(2) —C 2-6 alkenyl,
(3) —C 2-6 alkynyl,
wherein said alkyl, alkenyl and alkynyl is unsubstituted or substituted with phenyl, which is unsubstituted or substituted with a group selected from:
(i) halo,
(ii) —C 1-6 alkyl,
(iii) —C 2-6 alkenyl,
(iv) —C 2-6 alkynyl,
(v) —OH, and
(vi) —O—C 1-6 alkyl,
(4) hydrogen;
R 2 is selected from the group consisting of:
(1) (R 4 —S(O) 2 N(R 7 )—,
wherein R 4 is independently selected from the group consisting of:
(a) —C 6 alkyl,
(b) —C 2-6 alkenyl,
(c) —C 2-6 alkynyl,
wherein said alkyl, alkenyl and alkynyl is unsubstituted or substituted with one to six fluorus,
(d) phenyl, and
(e) benzyl,
wherein R 7 is independently selected from the group consisting of:
(a) hydrogen,
(b) —C 1-6 alkyl,
(c) —C 2-6 alkenyl,
(d) —C 2-6 alkynyl,
(2)
wherein R 8a and R 8b are independently selected from the group consisting of:
(a) hydrogen,
(b) —CN,
(c) halo,
(d) —C 1-6 alkyl,
(e) —C 2-6 alkenyl, and
(f) —C 2-6 alkynyl
R 3 is selected from the group consisting of:
R 6a , R 6b , and R 6c are independently selected from the group consisting of:
(1) hydrogen, and
(2) halogen;
R 5 is selected from the group consisting of:
(1) —C 1-6 alkyl,
(2) —C 2-6 alkenyl,
(3) —C 2-6 alkynyl,
wherein said alkyl, alkenyl and alkynyl is unsubstituted or substituted with phenyl, and
(4) hydrogen;
R 13 is selected from the group consisting of —CH═CH— and —O—;
R 9 and R 10 are independently selected from the group consisting of:
(1) hydrogen,
(2) C 1-6 alkyl,
(3) C 2-6 alkenyl,
(4) C 2-6 alkynyl, wherein said alkyl, alkenyl and alkynyl is unsubstituted or substituted with phenyl,
or R 9 and R 10 may be joined together to form a pyrrolidine or piperidine ring which is unsubstituted or substituted with —C 1-6 alkyl, —C 2-6 alkenyl, —C 2-6 alkynyl, —C 1-6 alkyl—O—C 1-6 alkyl, phenyl or pyridyl;
R 11 is selected from the group consisting of:
(1) —OH,
(2) —O—C 1-6 alkyl,
(3) —O—C l-6 alkyl-phenyl,
(4) —O—phenyl, and
(5) phenyl;
R 12 is selected from the group consisting of:
(1) —NR 9 R 10 , and
(2) —OH;
m is independently 0, 1, or 2;
and pharmaceutically acceptable salts thereof.
2. The compound of claim 1 of the formula II:
wherein:
R 1 is selected from the group consisting of:
(1) C 1-6 alkyl, unsubstituted or substituted with phenyl, and
(2) hydrogen;
R 2 is selected from the group consisting of:
(1) R 4 —S(O) 2 N(R 7 )—,
wherein R 4 is independently selected from the group consisting of:
(a) C 1-6 alkyl, which is unsubstituted or substituted with 1-6 fluoro,
(b) phenyl, and
(c) benzyl,
wherein R 7 is independently selected from the group consisting of:
(a) hydrogen, and
(b) —C 1-6 alkyl,
(2)
wherein R 8a and R 8b are independently selected from the group consisting of:
(a) hydrogen,
(b) —CN,
(c) halo, and
(d) —C 1-6 alkyl,
R 5 is selected from the group consisting of:
(1) C 1-6 alkyl, unsubstituted or substituted with phenyl, and
(2) hydrogen;
R 9 and R 10 are independently selected from the group consisting of:
(1) hydrogen, and
(2) C 1-6 alkyl, unsubstituted or substituted with phenyl;
R 11 is selected from the group consisting of:
(1) —OH,
(2) —O-phenyl, and
(3) phenyl.
3. The compound of claim 1 of the formula III:
wherein:
R 1 is selected from the group consisting of:
(1) C 1-6 alkyl, unsubstituted or substituted with phenyl, and
(2) hydrogen;
R 2 is selected from the group consisting of:
(1) R 4 —S(O) 2 N(R 7 )—,
wherein R 4 is independently selected from the group consisting of:
(a) C 1-6 alkyl, which is unsubstituted or substituted with 1-6 fluoro,
(b) phenyl, and
(c) benzyl,
wherein R 7 is independently selected from the group consisting of:
(a) hydrogen, and
(b) —C 1-6 alkyl,
(2)
wherein R 8a and R 8b are independently selected from the group consisting of:
(a) hydrogen,
(b) —CN,
(c) halo, and
(d) —C 1-6 alkyl,
R 5 is selected from the group consisting of:
(1) C 1-6 alkyl, unsubstituted or substituted with phenyl, and
(2) hydrogen;
R 11 is selected from the group consisting of:
(1) —OH,
(2) —O-phenyl, and
(3) phenyl.
4. The compound of claim 1 wherein R 1 is selected from the group consisting of:
(1) benzyl,
(2) phenyl-ethyl-,
(3) methyl, and
(4) hydrogen.
5. The compound of claim 1 wherein R 2 is CH 3 —S(O) 2 N(CH 3 )—.
6. The compound of claim 1 wherein R 2 is cyano-phenyl—.
7. The compound of claim 1 wherein R 5 is methyl.
8. The compound of claim 1 wherein R 9 and R 10 are independently selected from the group consisting of:
(1) hydrogen, and
(2) methyl.
9. The compound of claim 1 wherein R 11 is —OH.
10. A compound which is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
11. A pharmaceutical composition comprising an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
12. A method for inhibition of beta-secretase activity in a mammal in need thereof which comprises administering to the mammal a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
13. A method for treating Alzheimer's disease in a patient in need thereof comprising administering to the patient an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.